Guobang Pharma Ltd (605507) — Cash Flow-to-Debt Ratio
Guobang Pharma Ltd (605507) has a Cash Flow-to-Debt Ratio of 0.14x as of September 2025, meaning its operating cash flow of CN¥311.27 Million could theoretically repay 0% of its total liabilities (CN¥2.30 Billion) in one year. Check 605507 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Guobang Pharma Ltd Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Guobang Pharma Ltd across 9 annual periods. Also explore Guobang Pharma Ltd total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Guobang Pharma Ltd (2017–2025)
Year-by-year debt coverage analysis for Guobang Pharma Ltd. For market capitalisation and broader financial context, see market value of Guobang Pharma Ltd.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | CN¥559.28 Million | CN¥2.43 Billion | ▼ -11.1% |
| 2024 | 0.26x | CN¥706.41 Million | CN¥2.73 Billion | ▲ +46.5% |
| 2023 | 0.18x | CN¥516.76 Million | CN¥2.92 Billion | ▼ -67.2% |
| 2022 | 0.54x | CN¥1.02 Billion | CN¥1.89 Billion | ▲ +456.8% |
| 2021 | -0.15x | CN¥-176.18 Million | CN¥1.17 Billion | ▼ -143.9% |
| 2020 | 0.34x | CN¥767.70 Million | CN¥2.23 Billion | ▲ +67.1% |
| 2019 | 0.21x | CN¥440.86 Million | CN¥2.14 Billion | ▼ -32.6% |
| 2018 | 0.31x | CN¥541.68 Million | CN¥1.77 Billion | ▲ +274.6% |
| 2017 | 0.08x | CN¥148.03 Million | CN¥1.82 Billion | — |